search
Back to results

The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject

Primary Purpose

Diabetes

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
HR011408 injection; NovoRapid®
NovoRapid®;HR011408 injection
HR011408 injection; NovoRapid®
NovoRapid®;HR011408 injection
Sponsored by
Jiangsu HengRui Medicine Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Informed consent obtained prior to any trial-related activities; Male or female subjects aged 18-55 years (both inclusive) at the time of signing informed consent; Body weight ≥50.0 kg for men and ≥45.0 kg for women, with body mass index (BMI) between 18.0 and 26.0 kg/m2 (both ends included); Are nonsmokers, have not smoked for at least 6 months before entering the study, and agree not to smoke (cigars, cigarettes, or pipes) or not use smokeless tobacco or nicotine products for the duration of the study. Exclusion Criteria: Have an abnormality in the 12-lead electrocardiogram (ECG) and as deemed to be clinically significant by the investigator; have a significant history of the circulatory system, respiratory system, digestive system, urinary system, hematopoietic system, endocrine and metabolic system, neuropsychiatric system, musculoskeletal system, or existing diseases in the above systems may affect the safety of the subjects and interfere with the study data. In the opinion of the investigator, are unsuitable for inclusion in the study.

Sites / Locations

  • West China Hospital of Sichuan UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Cohort 1

Cohort 2

Cohort 3

Cohort 4

Arm Description

HR011408 injection + NovoRapid®

NovoRapid® + HR011408 injection

HR011408 injection + NovoRapid®

NovoRapid® + HR011408 injection

Outcomes

Primary Outcome Measures

Area under the concentration-time curve (AUC0-0.5h)
Area under the concentration-time curve (AUC)

Secondary Outcome Measures

Area under the concentration-time curve (AUC0-15min)
Area under the concentration-time curve (AUC0-1h)
Area under the concentration-time curve (AUC0-1.5h)
Area under the concentration-time curve (AUC0-2h)
Area under the concentration-time curve (AUC0-10h)
Area under the concentration-time curve (AUC0-inf)
Onset of appearance
First time point after dose administration when concentration reaches lower limit of quantification (LLOQ)
Time to 50% maximum observed concentration (time to 50% Cmax)
Time to maximum observed concentration (Tmax)
Maximum observed concentration (Cmax)
Elimination half-life (t1/2)
Area under the GIR-time curve (AUC)
Area under the GIR-time curve (AUC0-10h)
Time to 50% maximum observed GIR(time to 50% GIRmax)
Time to maximum observed GIR (GIRmax)
Incidence and severity of adverse events (AEs)

Full Information

First Posted
February 12, 2023
Last Updated
April 10, 2023
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05737576
Brief Title
The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject
Official Title
A Single Center, Randomized, Double-Blind, 2-period, 2-sequence Crossover Designed Study to Evaluate the Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 20, 2023 (Actual)
Primary Completion Date
May 30, 2023 (Anticipated)
Study Completion Date
June 16, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu HengRui Medicine Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The objective of the study is to compare the pharmacokinetics and pharmacodynamics between HR011408 and NovoRapid® in healthy subject.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Model Description
Crossover Assigned to HR011408 or NovoRapid®
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
44 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Experimental
Arm Description
HR011408 injection + NovoRapid®
Arm Title
Cohort 2
Arm Type
Experimental
Arm Description
NovoRapid® + HR011408 injection
Arm Title
Cohort 3
Arm Type
Experimental
Arm Description
HR011408 injection + NovoRapid®
Arm Title
Cohort 4
Arm Type
Experimental
Arm Description
NovoRapid® + HR011408 injection
Intervention Type
Drug
Intervention Name(s)
HR011408 injection; NovoRapid®
Intervention Description
HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.
Intervention Type
Drug
Intervention Name(s)
NovoRapid®;HR011408 injection
Intervention Description
NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.
Intervention Type
Drug
Intervention Name(s)
HR011408 injection; NovoRapid®
Intervention Description
HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.
Intervention Type
Drug
Intervention Name(s)
NovoRapid®;HR011408 injection
Intervention Description
NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.
Primary Outcome Measure Information:
Title
Area under the concentration-time curve (AUC0-0.5h)
Description
Area under the concentration-time curve (AUC)
Time Frame
from 0 to 30 minutes after dose administration
Secondary Outcome Measure Information:
Title
Area under the concentration-time curve (AUC0-15min)
Time Frame
from 0 to 15 minutes after dose administration
Title
Area under the concentration-time curve (AUC0-1h)
Time Frame
from 0 to 1 hour after dose administration
Title
Area under the concentration-time curve (AUC0-1.5h)
Time Frame
from 0 to 1.5 hours after dose administration
Title
Area under the concentration-time curve (AUC0-2h)
Time Frame
from 0 to 2 hours after dose administration
Title
Area under the concentration-time curve (AUC0-10h)
Time Frame
from 0 to 10 hours after dose administration
Title
Area under the concentration-time curve (AUC0-inf)
Time Frame
from 0 to infinity after dose administration
Title
Onset of appearance
Description
First time point after dose administration when concentration reaches lower limit of quantification (LLOQ)
Time Frame
from 0 to 8 hours after dose administration
Title
Time to 50% maximum observed concentration (time to 50% Cmax)
Time Frame
from 0 to 8 hours after dose administration
Title
Time to maximum observed concentration (Tmax)
Time Frame
from 0 to 8 hours after dose administration
Title
Maximum observed concentration (Cmax)
Time Frame
from 0 to 8 hours after dose administration
Title
Elimination half-life (t1/2)
Time Frame
from 0 to 8 hours after dose administration
Title
Area under the GIR-time curve (AUC)
Description
Area under the GIR-time curve (AUC0-10h)
Time Frame
from 0 to 10 hours after dose administration
Title
Time to 50% maximum observed GIR(time to 50% GIRmax)
Time Frame
from 0 to 10 hours after dose administration
Title
Time to maximum observed GIR (GIRmax)
Time Frame
from 0 to 10 hours after dose administration
Title
Incidence and severity of adverse events (AEs)
Time Frame
from Day1 to Day14 after dose administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Informed consent obtained prior to any trial-related activities; Male or female subjects aged 18-55 years (both inclusive) at the time of signing informed consent; Body weight ≥50.0 kg for men and ≥45.0 kg for women, with body mass index (BMI) between 18.0 and 26.0 kg/m2 (both ends included); Are nonsmokers, have not smoked for at least 6 months before entering the study, and agree not to smoke (cigars, cigarettes, or pipes) or not use smokeless tobacco or nicotine products for the duration of the study. Exclusion Criteria: Have an abnormality in the 12-lead electrocardiogram (ECG) and as deemed to be clinically significant by the investigator; have a significant history of the circulatory system, respiratory system, digestive system, urinary system, hematopoietic system, endocrine and metabolic system, neuropsychiatric system, musculoskeletal system, or existing diseases in the above systems may affect the safety of the subjects and interfere with the study data. In the opinion of the investigator, are unsuitable for inclusion in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hong Chen
Phone
0518-82342973
Email
hong.chen@hengrui.com
First Name & Middle Initial & Last Name or Official Title & Degree
Sheng Feng
Phone
0518-82342973
Email
sheng.feng@hengrui.com
Facility Information:
Facility Name
West China Hospital of Sichuan University
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ping Feng, Doctor
Phone
028-85423583
Email
617130961@qq.com
First Name & Middle Initial & Last Name & Degree
Yerong Yu, Doctor
Phone
028-85422982
Email
yerongyu@scu.edu.cn

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject

We'll reach out to this number within 24 hrs